Découvrez nos posters présentant les dernières avancées de notre plateforme

 Posters RCPG

PEGS Boston 2024: Discovery and Characterization of Biased Agonist and Antagonist hCCR5 Antibodies Using 3rd Generation ebBRET Biosensors.

PEGS Europe 2023: Early-stage Development of an in vitro Screening Assay to Characterize the Activation of the Human Adhesion GPCR ADGRE5.

GPCR Retreat 2023: Monitoring AT1R:A2C-AR Receptor Heterodimerization Using bioSens-All®.

Neuropsychiatric Drug Development Summit 2023: Development of a BRET biosensor-based screening strategy for identifying drivers of hallucinogenic activity of 5HT2AR targeting compounds.

ASPET 2023: Early-stage development of an in vitro screening assay to characterize the activation of the human adhesion GPCR ADGRE5.  Presented by Herthana Kandasamy and Arturo Mancini.

SLAS 2023: High-throughput applications for screening GPCR activation using bioSens-All®. Presenter by Frank Cao.

ASPET 2022: Large-scale profiling of physiologically relevant naturally occurring rare human GPCR variants using the bioSens-All® technology

ASPET 2021: Use of novel ebBRET biosensors for comprehensive signaling profiling of one hundred therapeutically relevant human GPCRs

SLAS 2020: Creation of a large-spectrum GPCR biosensor for functional in vitro safety and systems pharmacology analysis

IBS 2016: 3D-specific chicken antibodies targeting GPCR extracellular loops

Posters RTK

AACR 2021: EGFR Signaling and pharmacology in oncology revealed with an innovative RTK biosensor technology

Discovery on Target 2018: bioSens-All®: Openning up new frontiers in RTK drug discovery

Posters ICP

AACR 2021: A high value pharmacological platform dedicated to the real time study of stimulatory immune checkpoint signaling pathways